Also known as: BostonGene
BostonGene won the "Overall AI-based Analytics Company of the Year" award in the 9th annual AI Breakthrough Awards. Its platform pairs AI with molecular profiling to support oncology drug development decisions.
BostonGene announced a strategic collaboration with Daiichi Sankyo to integrate AI-driven analytics into an ADC development program. The company also revealed six abstracts will be presented at the EHA 2026 Congress in Stockholm. The research showcases integrated multiomics and predictive modeling for blood cancer treatment optimization.
Daiichi Sankyo is collaborating with BostonGene to integrate AI-driven translational intelligence into an antibody drug conjugate development programme. The work is aimed at biomarker discovery, response prediction, patient selection and trial design across its cancer pipeline.
